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RESUMO 
 
A leishmaniose, doença parasitária com manifestações clínicas diversas, é 
considerada uma das mais importantes patologias parasitárias. É causada por cerca de 
20 espécies de protozoários intracelulares do género Leishmania sendo, na maioria dos 
casos, uma zoonose de mamíferos selvagens ou domésticos que atinge acidentalmente 
o Homem. Este parasita é transmitido aos hospedeiros vertebrados pela picada de 
flebotomídeos do género Phlebotomus no Velho Mundo e Lutzomyia no Novo Mundo. 
O ciclo de vida deste inclui dois estadios com duas formas morfológicas distintas: forma 
amastigota no interior dos macrófagos do hospedeiro vertebrado e forma promastigota 
no intestino do insecto vector. Com base nas suas manifestações clínicas a 
leishmaniose pode ser classificada em três tipos principais: leishmaniose cutânea, 
leishmaniose mucocutânea e leishmaniose visceral. Leishmania infantum é o agente 
responsável pela leishmaniose visceral zoonótica, manifestação severa e mortal da 
doença, que se distribui pela região da bacia do Mediterrâneo incluindo Portugal.  
Há mais de 70 anos que os antimoniais pentavalentes (SbV), como estibogluconato 
de sódio (STB) e antimoniato de meglumina (MGA), têm sido usados como tratamento 
de primeira linha em todas as manifestações clínicas da doença. Estes fármacos, apesar 
de serem bastante eficazes no combate à leishmaniose, apresentam toxicidade 
elevada, sendo responsáveis por efeitos secundários graves. Nos últimos anos, a 
sensibilidade do parasita a estes fármacos tem sofrido alterações problemáticas em 
algumas regiões endémicas para Leishmania. Novos fármacos mais eficazes e/ou 
menos tóxicos têm vindo a ser usados em resposta à diferenciação de estirpes do 
parasita com menor sensibilidade aos antimoniais ou em situações clinicas de maior 
gravidade. Porém, o elevado custo torna impossível a utilização regular destes fármacos 
nos países mais afectados, uma vez que esta doença está frequentemente associada a 
países de baixa renda. Apesar da elevada quantidade de fármacos anti-Leishmania 
actualmente em uso, nenhum deles conjuga elevada eficiência, baixa toxicidade e custo 
acessível às populações afectadas. No seu conjunto, estes factores fazem da 
investigação de novos fármacos anti-Leishmania uma prioridade. Actualmente a 
investigação de novos fármacos está muito focada em compostos existentes com 
actividade terapêutica dirigida a outras doenças, compostos de origem natural ou 
formulações de herbicidas. Entre estes últimos compostos encontram-se os derivados 
de dinitroanilinas, nomeadamente a orizalina (ORZ) e compostos análogos da trifluralina 
(TFL), tendo o seu potencial no tratamento de leishmaniose sido demonstrado. 
A diminuição da sensibilidade do parasita aos fármacos em uso foi relacionada com 
a habilidade de amplificar selectivamente o número de cópias de alguns genes em 
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resposta ao contacto com as formulações. A amplificação génica é considerada o 
principal mecanismo de resistência a fármacos dentro do género Leishmania. O 
pequeno genoma e a reduzida quantidade de genes fazem deste parasita um alvo ideal 
para o estudo deste fenómeno. A ausência de controlo da transcrição é também um dos 
factores de sucesso da amplificação génica como mecanismo adaptativo, tendo sido 
demonstrado que o DNA amplificado pode atingir 10% do DNA total do parasita. 
Alterações na permeabilidade da membrana, permitindo uma inferior acumulação do 
fármaco dentro da célula, redução na importação do fármaco, inactivação do fármaco 
ou sequestro em compartimentos intracelulares são os mecanismos usados por 
Leishmania para sobreviver ao contacto com fármacos anti-Leishmania. O aumento do 
número de cópias dos genes das proteínas responsáveis por estes mecanismos está 
directamente relacionado com o aumento do respectivo nível de expressão mas também 
com o aumento da probabilidade de ocorrência de mutações pontuais em algumas 
destas cópias que poderão vir a ser vantajosas para a sobrevivência do parasita quando 
em contacto com fármacos. 
Neste estudo foi avaliado o potencial anti-Leishmania em modelo animal de um 
fármaco anti-Leishmania clássico, o estibogluconato de sódio, da dinitoanilina orizalina 
e de novos compostos sintéticos análogos da trifluralina, TFL-A3 e TFL-A6, que 
demonstraram elevada actividade anti-Leishmania e baixa toxicidade in vitro. Em 
modelo animal o tratamento não conduz à eliminação completa dos parasitas, tendo-se 
colocado em hipótese que os parasitas sobreviventes serão menos sensíveis ou 
resistentes aos fármacos usados. Neste estudo os parasitas que sobreviveram ao 
tratamento foram quantificados e recolhidos para extracção de DNA e o número de 
cópias de genes seleccionados foi quantificado por PCR em tempo real. Estudos 
anteriores efectuados em amostras recolhidas de pacientes de áreas endémicas de 
leishmaniose demonstraram que a menor susceptibilidade do parasita aos fármacos 
está relacionada com a amplificação dos seguintes genes: os genes para os 
transportadores de membrana MRPA (MRPA) e MDR1 (MDR1), o gene para a enzima 
gama-glutamil-cisteína sintetase (GSH1), envolvida na síntese de glutationa e 
tripanotiona, e o gene para a enzima pteridina redutase (PTR1), que intervém na cascata 
metabólica do folato. A quantificação absoluta do número de cópias de cada gene por 
parasita foi possível recorrendo a um gene de cópia única no genoma de Leishmania, o 
gene para a subunidade catalítica alfa da DNA polimerase. Foi também analisada a 
amplificação génica dos quatro genes seleccionados na forma promastigota do parasita 
(in vitro). Promastigotas de L. infantum foram tornados resistentes a antimoniato de 
meglumina, miltefosina, TFL-A3 e TFL-A6, e o número de genes quantificado por PCR 
em tempo real. 
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Foi demonstrado que a actividade anti-Leishmania dos compostos TFL-A6 e 
orizalina é bastante promissora, sendo muito semelhante à actividade do 
estibogluconato de sódio. TFL-A3 apresentou actividade anti-Leishmania mais reduzida.   
Os parasitas que in vivo sobreviveram ao tratamento com estibogluconato de sódio 
apresentaram aumento significativo do número de cópias dos genes MDR1 e PTR1, 
sugerindo amplificação da capacidade de expulsão deste fármaco do interior do parasita 
e alterações na via metabólica do folato, reduzindo a quantidade de intermediários de 
espécies reactivas de oxigénio e azoto. Apesar de existirem duvidas devido ao facto das 
amostras serem provenientes de doentes que poderiam ter estado sujeitos a fármacos 
adicionais, a amplificação de MDR1 tinha sido demonstrada em estudos anteriores. O 
presente estudo vem mostrar que a amplificação de MDR1 ocorre de facto em parasitas 
que estiveram unicamente em contacto com estibogluconato de sódio. Os parasitas 
provenientes de murganhos tratados com TFL-A3 apenas apresentaram aumento do 
número de cópias do gene MDR1. Os parasitas isolados a partir do grupo tratado com 
TFL-A6 apresentaram amplificação dos genes MDR1, MRPA e PTR1. Esta amplificação 
indica que o mecanismo de resistência está associado ao efluxo do fármaco pelo 
parasita, ao sequestro do fármaco para compartimentos intracelulares do parasita e a 
alterações na quantidade de espécies reactivas de oxigénio e azoto que se formam. Nos 
parasitas que estiveram em contacto com a orizalina os genes GSH1, MDR1 e PTR1 
apresentam aumento do número de cópias. No caso da orizalina o mecanismo usado 
parece estar relacionado com o aumento de efluxo do composto, alterações na 
quantidade de espécies reactivas de oxigénio e azoto e alterações no balanço do 
potencial reductor no interior do parasita. Nas experiências in vitro os promastigotas 
resistentes a antimoniato de meglumina, miltefosina, TFL-A3 ou TFL-A6 demonstraram 
resultados distintos dos encontrados nos parasitas resultantes dos murganhos que 
foram sujeitos a tratamento. Estas diferenças podem ser explicadas pelo modo como 
diferentes formas morfológicas do parasita reagem quando contactam com o fármaco. 
Nas experiências in vivo a forma amastigota encontrava-se internalizada pelos 
macrófagos do hospedeiro, retida no interior dos fagolisossomas, enquanto nas 
experiências in vitro a forma promastigota encontrava-se livre no meio de cultura. Os 
diferentes ambientes (amastigota – intracelular, rodeado por duas membranas, pH 
ácido, 37ºC, sujeito a acções do sistema imunitário do hospedeiro; promastigota – livre, 
meio de cultura, pH neutro, 24ºC) induzem a diferenciação pelo parasita de diferentes 
mecanismos de adaptação e sobrevivência. Os promastigotas resistentes a antimoniato 
de meglumina demonstraram um aumento significativo do número de cópias de GSH1 
e redução do número de cópias de MDR1. Os parasitas resistentes a miltefosina não 
apresentaram qualquer alteração significativa no número dos genes estudados. Os 
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parasitas resistentes a TFL-A3 apresentaram amplificação do gene GSH1 e os 
resistentes a TFL-A6 demonstraram um aumento significativo do número dos genes 
GSH1, MDR1 e PTR1. 
Com este estudo é possível concluir que uma elevada actividade anti-Leishmania e 
uma baixa toxicidade pode não ser suficiente para um composto ser considerado uma 
boa alternativa aos fármacos actualmente usados. Resistência a TFL-A6 parece dever-
se a indução de mecanismos semelhantes aos responsáveis pela resistência aos 
fármacos actualmente em uso. O desenvolvimento de menor sensibilidade ou 
resistência pode conduzir à rápida diminuição da eficiência anti-Leishmania deste 
composto ou mesmo à ineficácia no combate a estirpes já resistentes aos fármacos em 
uso. Todos estes factores devem ser tidos em consideração no desenvolvimento de 
novos compostos anti-Leishmania, prevenindo o aparecimento de estirpes menos 
susceptíveis mas também como forma de minimizar o investimento em fármacos que à 
partida não deveriam ser considerados como alternativa para tratamento da 
leishmaniose. 
 
Palavras-chave: Leishmaniose, Leishmania infantum, resistência, novos fármacos, 
amplificação génica.  
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ABSTRACT 
 
Leishmaniasis, caused by intracellular protozoa of the genus Leishmania, is 
considered one of the most important human parasitic diseases in the world. Leishmania 
infantum is the agent responsible for zoonotic visceral leishmaniasis, the most severe 
and fatal form of the disease, in the Mediterranean region, including Portugal. Recently, 
the variation of parasite sensitivity to several drugs became a problem in some endemic 
areas for Leishmania. It was observed that the ability of Leishmania to selectively 
increase the number of gene copies is the main adaptation of these parasites to drug 
pressure, therefore responsible for resistance. Furthermore, all the currently used 
antileishmanial drugs do not conjugate high efficiency, low toxicity and an affordable 
cost. Therefore the development of new therapeutic compounds for leishmaniasis still is 
a priority. The potential of trifluralin (TFL) for the treatment of leishmaniasis was recently 
demonstrated and two analogues, TFL-A3 and TFL-A6, which presented higher 
antileishmanial activity and less cytotoxicity than TFL were analyzed in the present study. 
Another drug, oryzalin (ORZ), and conventional antileishmanial drugs (sodium 
stibogluconate, meglumine antimoniate and miltefosine) were also assessed. In vivo and 
in vitro studies were performed to confirm their antileishmanial activity and to access 
their potential to induce drug resistance in L. infantum. The genes for ABC-thiol 
transporter (MRPA), P-glycoprotein (MDR1), the enzyme gamma-glutamylcysteine 
synthase (GSH1) and pteridine reductase 1 (PTR1), already associated with drug 
resistance in previous studies, were selected and quantified by real-time PCR. The 
results revealed that TFL-A6 and ORZ have an antileishmanial potential similar to the 
conventional antileishmanial drugs. However, it was demonstrated that a relatively short 
period of treatment (10 days) is enough to induce significant gene amplification in the 
parasites that survived in vivo to the treatment. In vitro experiments demonstrated that 
the level of gene amplification in the promastigote form is different than in the intracellular 
amastigote form of the parasite when exposed to the same drugs. This study 
accentuates the need for understanding the mechanisms and evaluate the appearance 
of resistances when designing and investigating new antileishmanial drugs. 
 
Keywords: Leishmaniasis, Leishmania infantum, drug resistance, new drugs, gene 
amplification. 
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I. INTRODUCTION 
I. INTRODUCTION 
 
1. Leishmaniasis 
 
1.1. Epidemiology 
 
Leishmaniasis is a parasitic disease caused by intracellular protozoa belonging to the 
family Trypanosomatidae Doflein, 1901 and the genus Leishmania Ross, 1903 [Shaw, 
1994; Croft et al., 2006]. More than 20 species of Leishmania were identified as 
responsible for the disease in humans [Schallig & Oskam, 2002]. The parasite is 
transmitted to the vertebrate host by sandflies of the genus Phlebotomus Rondani & 
Berté, 1843 in the Old World and Lutzomyia França, 1924 in the New World [Desjeux, 
2001]. 
Leishmania infections are in most cases zoonosis from wild or domestic mammals, 
and accidentally the parasite infects humans, although in East Africa and Indian 
subcontinent anthroponotic form of the disease can be found. The main domestic animal 
reservoirs are the dogs, while the sylvatic ones are small rodents and larger mammals, 
like foxes, wolves and jackals. 
 
 
1.1.1. In humans 
 
Leishmaniasis is considered one of the most important human parasitic diseases in 
the world, both in mortality and morbidity. According to the World Health Organization 
(WHO) there is an estimate of 2 million new cases every year, 350 million people are at 
risk of being infected, around 12 million people are already infected and 60 000 die every 
year. Increase of incidence and severity of this disease is due to infected human and 
dog migration, global warming altering the distribution of the vector, co-infection with 
immunosuppressive diseases and poverty [Desjeux, 2001; Neuber, 2008; Alvar et al., 
2012]. 
Leishmaniasis different clinical manifestations can be classified into three types: 
cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (ML) and visceral 
leishmaniasis (VL). 
Cutaneous leishmaniasis is the most common form of the disease. The clinical 
manifestations can go from a single self-healing skin lesion to multiple localized or 
diffused lesions leading to a chronic state [Sádlová, 1999]. The clinical outcome depends 
mostly on the species of the parasite, but it is also influenced by the species of the vector 
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and the innate or acquired resistance of the human host [Herwaldt, 1999]. Although the 
majority of the cases lead to spontaneous healing and the skin lesions disappear in less 
than a year, around 15% of the cases lead to relapses and 2 to 40% of the cases of CL 
evolve into the mucocutaneous form of the disease. The species responsible for this 
form of leishmaniasis are: Leishmania major, L. tropica, L. aethiopica, L. infantum, L. 
shawi, L. mexicana, L. amazonensis, L. braziliensis, L. peruviana, L. panamiensis, L. 
guyanensis, L. lainsoni and L. naiffi [Murray et al., 2005; Neuber, 2008].  
Mucocutaneous leishmaniasis consists in a progression of the cutaneous form, it 
happens when the infection reaches the mucosal regions. Can affect and destroy the 
tissues of the oronasal and pharyngeal cavities, and can lead to severe and painful facial 
mutilations. This form can happen as soon as one week after the appearance of the first 
skin lesion as well as many years after the cutaneous manifestations, showing that the 
parasite persists in the tissues for a long time. The species responsible for this form of 
leishmaniasis are: L. braziliensis, L. panamensis and L. guyanensis. There are also 
reports of mucocutaneous leishmaniasis caused by L. donovani, L. major and L. infantum 
in individuals with immunosuppressive diseases [Desjeux, 1996]. 
Visceral leishmaniasis is the most severe and fatal form of the disease, comprising a 
broad range of clinical manifestations. The parasite invades and multiplies in the organs 
of mononuclear phagocyte system such as the spleen, liver and lymph nodes and the 
symptoms are characterized by prolonged and irregular fever, splenomegaly, 
lymphadenopathy, hepatomegaly, pancytopenia, progressive anemia, weight loss and 
hypergamma-globulinemia with hypoalbuminemia. In many cases the infection does not 
take an acute or chronic course, remaining asymptomatic or subclinical and can even 
lead to a self-healing scenario [Sahni, 2012]. The species responsible for this form of 
leishmaniasis are: L. donovani and L. infantum [Berman, 1997]. 
 
 
1.1.2. In dogs 
 
Canine leishmaniasis (CanL) is a chronic and systemic disease with a broad spectrum 
of non-specific clinical manifestations caused by L. infantum in domestic dogs (Canis 
lupus familiaris). The most frequent manifestations are skin lesions, however, the 
animals can show other clinical signs unrelated to cutaneous lesions as their main 
symptoms such as renal disease or any other symptoms characteristic of human VL. 
Since infection with the parasite does not always mean clinical illness there is a high 
prevalence of subclinical and asymptomatic infected animals in the endemic regions. In 
addition to the fact that the domestic dogs share the same habitat, frequently contact 
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and often travel with humans, this makes dog the most important reservoir for L. 
infantum. Other species of Leishmania were also found infecting dogs (L. braziliensis, L. 
panamensis and L. peruviana) and even though this species do not cause disease in 
these animals it may be that dogs act as reservoirs for this species as well [Reithinger et 
al., 2003; Solano-Gallego et al., 2011; Palatnik-de-Sousa, 2012]. 
 
 
1.1.3. Geographic distribution 
 
Leishmania occurs mostly in tropical and sub-tropical areas and is present in all 
continents, except Antarctica. Until the last decade, it was thought that Oceania and 
Southeast Asia were Leishmania free but recent findings prove otherwise [Rose et al., 
2004; Conlan et al., 2011]. Endemic regions can be found in South and Central America, 
North and East Africa, Middle-East, Indian sub-continent, Central and Eastern Asia and 
South Europe, putting together a total of 98 countries considered endemic for 
Leishmania. More than 90% of all VL cases occur in just six countries: India, Bangladesh, 
Sudan, South Sudan, Brazil and Ethiopia. The prevalence of CL is more widely spread, 
with 70 to 75% occurring in ten countries around the globe: Afghanistan, Algeria, 
Colombia, Brazil, Iran, Syria, Ethiopia, North Sudan, Costa Rica and Peru [Alvar et al., 
2012]. 
In Portugal as in the Mediterranean Basin countries, the species responsible for the 
majority of leishmaniasis cases is L. infantum, both in humans and animals. There are 
reports of leishmaniasis across the entire continental territory of Portugal, but three areas 
stand out as the most important endemic regions: Metropolitan area of Lisbon, Alto 
Douro and Algarve. The prevalence of CanL can go up to 20% in these endemic areas 
and between 2000 and 2009 there were 173 new cases reported of VL, mostly in children 
and immunocompromised individuals [Santos-Gomes et al., 1998; Campino & Maia, 
2010]. 
 
 
1.2. Life cycle 
 
Leishmania is a dimorphic parasite: promastigote form (Figure 1) occurs in the 
invertebrate host (sandfly) and the vertebrate host has the amastigote form (Figure 2). 
The promastigote, found in the midgut of the insect vector, has an elongated shape and 
a well-developed anterior flagellum. It is possible to characterize two stages of 
promastigote development: the procyclic stage and the metacyclic stage. Procyclic 
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promastigotes are not infectious, 
are in continuous division and 
have a shorter flagellum. On the 
other hand, metacyclic promasti-
gotes are highly infectious, are 
long and narrow and have a large 
flagellum [Killick-Kendrick, 1990; 
Ashford, 2000]. Amastigotes have 
a round shape and no external 
flagellum.  Being an obligatory 
intracellular form it can only survi-
ve and multiply inside parasito-
phorous vacuoles of phagocytic 
cells. 
Parasites are transmitted to the 
vertebrate host when the infected female sandfly takes a blood meal, inoculating the 
promastigotes in the vertebrate’s dermis. Parasites are then phagocytized by 
macrophages and once inside the cell they transform into amastigotes. Amastigotes 
multiply inside phagocytic cells that are later ingested by another sandfly when it takes 
a blood meal. Ingested cells are digested in the sandfly gut and the free amastigotes 
reach the midgut where they 
transform into promastigotes. 
Promastigotes multiply and later 
migrate into the proboscis of the 
sandfly, from where they will be 
introduced into the vertebrate host 
dermis when a blood meal occurs 
[Cohen-Freue et al., 2007; 
Dostálová & Volf, 2012] (Figure 3).  
 
 
1.3. Parasite/vertebrate host 
interaction 
 
In the vertebrate, destruction of 
invading microorganisms is essen-
tially executed by two types of 
Figure 1. Schematic representation of a Leishmania 
promastigote. a – flagellum; b – axoneme; c – basal corpuscle; d – 
mitochondria; e – nucleus; f – subpellicular microtubules; g – 
glycosome; h – lipid inclusions; i – acidocalcisome; j – endoplasmic 
reticulum; k – multivesicular tubule; l – nucleolus; m – kinetoplast; n 
– Golgi complex. Adapted from Teixeira et al. (2013). 
Figure 2. Schematic representation of a Leishmania 
amastigote. a – basal corpuscle; b – lipid inclusions; c – 
subpellicular microtubules; d – mitochondria; e – megasome; f – 
glycosome; g – endoplasmic reticulum; h – nucleus; i – nucleolus; j 
– acidocalcisome; k – kinetoplast; l – Golgi complex; m – flagellar 
pocket; n – axoneme; o – flagellum. Adapted from Teixeira et al. 
(2013). 
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cells, the macrophages and the neutrophils. When inoculated in the vertebrate dermis, 
Leishmania promastigotes are phagocytized by macrophages (Figure 4). Within these 
cells, the parasites stay inside parasitophorous vacuoles that fuse with lysosomes 
Figure 3. Life cycle of Leishmania in the mammalian host and insect vector. 1 – Female sandfly takes a blood 
meal and inoculates the promastigotes; 2 – Promastigotes are phagocytized by macrophages; 3 – Transformation 
into amastigotes inside the parasitophorous vacuole; 4 – Amastigote replication; 5 – Ingestion of infected 
macrophages or free amastigotes by the female sandfly when taking a blood meal; 6 – Transformation into 
promastigotes in the sandfly midgut; 7 – Promastigotes replication and transformation into metacyclic 
promastigotes. Adapted from Teixeira et al. (2013). 
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containing proteolytic enzymes, forming phagolysosomes [Bogdan & Röllinghoff, 1998]. 
Within phagolysosomes production of reactive oxygen and reactive nitrogen molecules 
occur in order to destroy the 
invader organism [Slauch, 2011]. 
Leishmania has the ability to slow 
down the fusion of these vacuoles 
assuring the successful transfor-
mation into amastigotes. Amasti-
gotes present high enzymatic 
activity and using catalase, 
superoxide dismutase and 
glutathione peroxidase are able 
to eliminate the products of 
oxidative burst [Meshnick & Eaton, 1981; Murray, 1981]. The lipophosphoglycan of 
Leishmania is also a potent inhibitor of the proteins responsible for activation of oxidative 
burst as well as capable of interfering with the production of nitric oxide inside the 
phagolysosomes [Bogdan & Röllinghoff, 1998]. 
 
 
1.4. Diagnostic 
 
Because of the wide spectrum of clinical manifestations this disease represents a 
diagnostic challenge, requiring confirmatory tests to decide if patients should be treated. 
These tests require a high sensitivity and specificity due to the leishmaniasis clinical 
severity and to the fact that drugs currently used for the treatment have high toxicity and 
can be very expensive. Microscopy still is the standard technique for leishmaniasis 
diagnosis in endemic areas [Reithinger & Dujardin, 2007]. Giemsa-stained lesion biopsy 
smears or aspirates from the lymph node, bone marrow or spleen are used with high 
specificity to identify the presence of the parasite. Laboratory cultures of the biopsies 
and aspirates are also used to diagnose leishmaniasis. However, microscopy and culture 
diagnosis tend to have low sensitivity and be highly variable [Herwaldt, 1999]. Several 
immunological techniques are also used as complementary to direct parasitological 
detection. Tests based on indirect fluorescence antibody, enzyme-linked immunosorbent 
assay and western blot have shown high diagnostic accuracy. Two serological tests were 
specifically developed for VL, the direct agglutination test and the rK39-based 
immunochromatographic test. Both tests showed values higher than 90% for both 
sensitivity and specificity [Chappuis et al., 2007]. One test was developed for CL, the 
Figure 4. Scanning electron microscopy micrograph of a 
Leishmania promastigote being phagocytized by a macrophage. 
Adapted from Teixeira et al. (2013). 
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Montenegro skin test where an intradermal injection of dead promastigotes is given to 
the patient and examined 48 hours later to see if a delayed-type hypersensitivity has 
formed. This test has a very high sensitivity and specificity however does not distinguish 
between past and present infections. The most reliable approach in leishmaniasis 
diagnosis at this moment is the molecular approach based on polymerase chain reaction 
(PCR) assays. PCR has the highest sensitivity and specificity (up to 100%) of all the 
diagnostic methods for leishmaniasis, can diagnose independently of parasite species 
and have been shown to be better than direct parasitological test specially on samples 
with low parasite loads or samples from less intrusive sources [Reithinger & Dujardin, 
2007]. 
 
 
1.5. Control 
 
Control strategies focus on two major areas: vector control and reservoir control. For 
vector control the most widely strategy used is the spraying of households with 
insecticide and the use of insecticide treated curtains and bed nets. However this 
strategy was only proved to be effective in small cluster areas and the results cannot be 
extrapolated elsewhere [Davies et al., 2003]. For reservoir control there are several 
strategies. The culling of dogs have been widely used in Brazil and China. But while in 
China the indiscriminate culling of dogs had positive results, recent studies showed that 
has not been effective in Brazil, where only serological positive dogs were euthanized. 
The use of insecticide treatment of dogs and insecticide dog collars has shown good 
results in controlling parasite transmission to humans. The treatment of reservoirs has 
also shown good results in reducing transmission [Piscopo & Azzopardi, 2006]. With the 
recent introduction of vaccines for CanL (in Europe and Brazil) a decrease in parasite 
transmission is expected, but is still too soon to reach conclusions. 
 
 
1.6. Treatment 
 
The first-line treatment for every type of leishmaniasis still remains the pentavalent 
antimonials (SbV) in the forms of sodium stibogluconate (STB) and meglumine 
antimoniate (MGA). In many endemic areas these drugs have been used in the combat 
of Leishmania infection for more than 70 years. In the last two decades cheaper generic 
forms with equivalent results of the branded products emerged and its use was even 
more widespread. Despite having good efficacy these drugs are also toxic and 
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responsible for life-threatening adverse side effects, including cardiac arrhythmia and 
acute pancreatitis [Chappuis et al., 2007]. STB (100 mg/ml of SbV) and MGA (85 mg/ml 
of SbV) are given intravenously and intramuscularly, usually at a dose of 20 mg of 
SbV/kg/day for up to 28 days, with a recommended maximum dose of 850 mg/day. 
Shorter periods of treatment have been proposed with equal efficiency (minimum of 10 
days) [Wortmann et al., 2002] but this may increase the predisposition to drug-resistance 
even more [Piscopo & Azzopardi, 2006]. In some areas, especially in India, the failure 
rate for treatment with SbV is more than 50% due to drug-resistance [Sundar, 2001], 
largely because of inappropriate use of antimony treatment. Because of the increasing 
drug-resistance and the adverse side-effects, research on new drugs was continued and 
lead to second-line drugs, amphotericin B (AmB) and miltefosine (MILT), most commonly 
used nowadays to fight resistant infections or the most severe cases of the disease.  
AmB is mostly used in resistant cases of leishmaniasis where the SbV treatment fails, 
but its high toxicity and prolonged period of treatment (given intravenously for up to 60 
days) are a limiting factor despite the high cure rate (97%). An alternative is the liposomal 
form of AmB which is equally effective but less toxic. However it is still prohibitively 
expensive, especially in poor countries where the resistances to SbV are more significant 
and this drug is needed most [Piscopo & Azzopardi, 2006]. In Southern Europe the use 
of this drug as a first line-treatment to replace SbV have increased, possibly because the 
access to the drug is economically less restrictive and because of the growing resistance 
to SbV augmented by the use of MGA to treat dogs with leishmaniasis [Gradoni et al., 
2003]. 
MILT is the first effective drug against Leishmania (94% cure rate) to be taken orally. 
MILT is a simple, very stable, relatively safe and highly efficient molecule with the 
capacity not only to directly kill Leishmania parasites but also to enhance both T cell and 
macrophage activation and the production of reactive nitrogen and oxygen intermediates 
by these cells [Soto et al., 2007]. These properties and the potential to be distributed in 
resource-poor areas make this drug an excellent candidate for a generalized first-line 
drug. However concerns about compliance with treatment and resistance have already 
been expressed [Murray et al., 2005]. 
Other compounds have been proven efficient antileishmanial drugs, particularly drugs 
directed for CL treatment. Pentamidine, paromycin, fluconazole and ketoconazole are 
examples of drugs already used in the treatment of CL, but as the more commonly used 
first-line drugs there are life-threatening adverse side effects and the potential for the 
emergence of drug-resistance. Drugs as allopurinol and imiquimod are also being used 
in the treatment of leishmaniasis in combination with SbV in cases of drug resistance or 
very severe infections [Piscopo & Azzopardi, 2006]. 
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2. Gene amplification in Leishmania 
 
2.1. Gene amplification 
 
When a slow accumulation of RNA and proteins is not enough for the normal 
functioning of the cells, multiple copies of genes can be found, allowing a faster 
expression than the one achieved from a single gene copy. Multiple gene copies can be 
found in most cells, although in some cases specific genes, or sets of genes, are 
amplified in specific types of cells. Developmentally regulated gene amplification is 
common. However, gene amplification not related to cell development has been 
described as an abnormal process found in both prokaryotes and eukaryotes. Gene 
amplification can be found within chromosomes or in extrachromosomal elements. 
Within chromosomes is found in homogeneously staining regions, following the same 
pattern of replication and segregation as the rest of the chromosome. The 
extrachromosomal elements can appear as either linear or circular amplicons, with direct 
(head-to-tail) or inverted (head-to-head) repeats. These amplicons usually lack 
centromeres and telomeres and in the absence of a selective pressure tend to be lost 
[Stark & Wahl, 1984]. Gene amplification has been studied and related to several 
adaptations, ranging from the transport of nutrients within the cells to adaptive 
modifications in domesticated animals, and also plays a major role in adaptation to 
antibiotics and drugs in several types of cells. This adaptation to drugs via gene 
amplification was reported and widely studied in mammal tumor cells [Kondrashov, 
2012]. 
Leishmania infantum, like other species of Leishmania, have a small genome 
(approximately 32100000 bp) with a small amount of genes (8241 coding genes), 
providing an easy target for gene amplification studies [Rogers et al., 2011]. Also, the 
unusual lack of transcriptional control of Leishmania, where expression is regulated 
almost exclusively by post-transcriptional mechanisms [Martínez-Calvillo et al., 2003; 
Martínez-Calvillo et al., 2010] is an advantage for success of gene amplification. Studies 
have shown that amplified DNA can reach as much as 10% of the total DNA in 
Leishmania, as extrachromosomal circular or linear amplicons. Subchromosomal 
amplifications were also reported in Leishmania, consisting of relatively small 
chromosomes (250000 bp or less) occurring in multiple copies (up to 40 per cell) and 
only present in some but not all isolates from numerous Leishmania species.  Initially 
thought that this was the result of some kind of horizontal transmission, current data 
suggest that is the result of extrachromosomal amplification where the amplicons 
acquired at least one new telomere during their formation, presumably by the action of 
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leishmanial telomerase. The greatest number of copies of these amplicons found in 
some isolates suggests evasion of the mechanisms that normally limit the number of 
chromosomes. Since no biological role for this subchromosomal amplicons have been 
demonstrated so far it is believed that they may provide subtle growth advantages, 
particularly during adaptation to in vitro culture [Beverley, 1991].  
 
 
2.2. Circular amplicons 
 
Opposite to tumor cells where there is little or no need of homologous sequences for 
the rearrangement of chromosomal sequences to produce circular amplicons, in 
Leishmania homologous sequences are needed for the generation of amplicons 
[Grondin et al., 1996]. Also, unlike mammalian amplifications, Leishmania amplifications 
appear to be homogenous and possess the minimum number of DNA rearrangements 
necessary to generate an amplicon from the chromosomal gene; one for the direct 
amplification (Figure 5a) and two for the inverted amplification (Figure 5b). They usually 
range from 30000 bp to 
200000 bp. Secondary 
rearrangements of amplified 
DNA were considered rare 
events in Leishmania but 
studies showed that gene 
amplification is more dyna-
mic than anticipated. It is 
now suggested that gene 
rearrangements leading to 
gene amplification are 
widespread and that circular 
amplicons are generated 
from linear amplicons 
[Grondin et al., 1998]. There 
are three types of amplifi-
cation described in Leishmania. Deletion amplification (Figure 6a), where the copy of 
wild-type chromosomal locus is deleted during the generation of the extrachromosomal 
amplicon, resulting in a heterozygous deletion line. Conservative amplification (Figure 
6b), where the generation of the amplicon produces no alterations in chromosomal 
structure or ploidy. And, duplicative amplification (Figure 6c), where several additional 
Figure 5. Schematic representation of DNA structures of direct 
amplification (a) and inverted amplification (b) in Leishmania. The blue 
boxes represent repetitive DNA sequences whose orientations are indicated 
by black arrows. Green arrows indicate the orientation of the gene being 
amplified (green line). 
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copies are found inserted into the locus in addition to the amplified amplicon. As stated 
before, this extrachromosomal amplicons can be either a result of direct amplification or 
inverted amplification [Beverley, 1991]. 
 
 
2.3. Mechanism 
 
Leishmania amplicons, whose structure have been characterized, seem to rule out 
gene amplification models that imply alteration of the parental chromosome structure 
(like sister chromatid exchange or recombination in the absence of re-replication). 
Extrachromosomal amplicons are likely to be generated from extra copies of the 
chromosomal locus formed by re-replication during the cell cycle. The onionskin model 
(Figure 7) seems to explain the initial structure of the re-replication. This hypothetical 
structure has this name 
because it resembles the skin 
layers of an onion when 
multiple rounds of replication 
initiate in the same origin 
within a single replication 
bubble in a given replication 
cycle. The flexibility of this 
model allows to virtually 
Figure 6. Schematic representation of deletion (a), conservative (b) and duplicative (c) amplification. The black 
lines represent flanking chromosomal DNA, the green lines represent DNA segments that give rise to 
extrachromosomal circular amplicons in addition to being either deleted, conserved or duplicated in the chromosome. 
Figure 7. Schematic representation of the onionskin model. 
Overreplication gives rise to a layer structure. The black lines represent 
genomic DNA and the blue areas correspond to repetitive DNA sequences 
flanking the DNA fragments (green) that will be amplified. 
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obtain all types of amplification. Unaltered DNA strands can maintain the normal 
chromosome structure after the collapse of the onionskin, and the copies generated are 
released as extrachromosomal amplicons, explaining this way the conservative 
amplification. Rearrangements in the chromosome strand can lead to deletion plus 
amplicon formation, explaining the deletion amplification. Rearrangements between the 
chromosomal strand and the replicated segments can lead to duplicative amplification 
within the chromosome, with the release of the extra copies generated as 
extrachromosomal amplicons. It also explains the generation of linear amplicons 
whenever the released copies acquire telomeres by the action of a leishmanial 
telomerase. Since the formation of amplicons in Leishmania is associated with 
homologous repetitive sequences it is supposed that these sequences give rise to 
hotspots for DNA rearrangement and amplification. Genes flanked by direct repeats 
undergo direct amplification (Figure 5a) while genes flanked by inverted repeats undergo 
inverted amplification (Figure 5b). The final step of the mechanism consists in the ability 
to increase and maintain the copy number of the circular amplicons. A selective pressure 
can ensure that a sufficient number of copies of a specific gene are maintained in the 
parasites. However, little is known about the mechanism for autonomous replication of 
the amplicons, only that no specific sequences seem to be required for replication 
[Beverley, 1991; Papadopoulou et al., 1994]. 
 
 
2.4. Response to drug pressure 
 
Leishmania differs from other closely related protozoan parasites in the reaction to 
drug pressure. In Trypanosoma brucei gene amplification is extremely rare and in 
parasites of genus Plasmodium the gene amplification is mainly chromosomal, therefore 
in these parasites the increase of gene copy number is very reduced, so other 
mechanisms of overexpression of multidrug resistance genes play an important role. On 
the other hand, it was observed that the ability of Leishmania to selectively increase the 
number of gene copies is responsible for resistance. This was possible due to the 
relatively low genomic complexity of Leishmania. Gene amplification, mostly as 
extrachromosomal amplicons, is now considered the main adaptation response of these 
parasites to drug pressure [Beverley, 1991; Papadopoulou et al., 1998]. Changes in 
membrane permeability, allowing a reduction of intracellular drug accumulation, or a 
decrease in drug intake and inactivation of the drug by metabolism or sequestration are 
the mechanisms used by Leishmania to survive when in contact with antileishmanial 
compounds. The increase of gene copy number will not only directly increase the level 
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of expression but also augment the probability of point mutations to appear, which may 
confer advantage to the parasite when in contact with antileishmanial drugs [Croft et al., 
2006]. 
 
 
3. Drug resistance in Leishmania 
 
3.1. Pentavalent antimonials 
 
Pentavalent antimonials (SbV) are considered pro-drugs. In order to acquire 
antileishmanial activity these compounds require biological reduction to the trivalent form 
(SbIII). Although the site of reduction remains unclear data suggests that it happens inside 
the parasite as well as within the macrophage. The pentavalent form is known to 
stimulate the infected macrophages, increasing the oxidative/nitrosative stress on the 
intracellular parasites. SbIII acts directly on the parasite, deregulating its redox-balance. 
SbV is taken up by the parasite by an unidentified transporter and SbIII enters via 
aquaglyceroporin (AQP1). Reduction of SbV to SbIII inside the parasite can be a thiol 
dependent non-enzymatical spontaneous reduction or enzymatically catalyzed by thiol-
dependent reductase 1 (TDR1) or arsenate reductase 2 (ACR2). Maintenance of redox 
balance inside the parasite is performed by trypanothione (T(SH)2) and trypanothione 
reductase (TR) which reduces trypanothione disulfides (TS2) to T(SH)2, keeping the 
redox potential low. T(SH)2 is synthesized by condensation of glutathione and 
spermidine, where gamma-glutamylcysteine synthase (GSH1) is the key enzyme for 
glutathione (GSH) synthesis. SbIII inhibits TR and can form conjugates with T(SH)2 and 
glutathione, leading to an increase in redox potential (Figure 8) [Wyllie et al., 2004; 
Decuypere et al., 2012].  
In order to acquire resistance to antimonials it was shown that Leishmania can use 
different strategies. A decrease in the reduction of SbV to SbIII, by reducing the levels of 
TDR1 and ACR2 inside the parasite leads to increase resistance. However, it is not 
effective in protecting from external SbIII. In strains exhibiting decreased susceptibility to 
SbIII a decrease in AQP1 expression was noted, although no difference in gene copy 
number was found. Decreasing the influx of SbIII is probably the first barrier of the 
parasite to counteract the action of antimonials. An increase in the synthesis of 
glutathione and trypanothione from cysteine was also reported in resistant strains. This 
helps to restore thiol redox potential perturbed by the accumulation of TS2, caused by 
the inhibition of TR activity by SbIII. It also increases the spontaneous formation of SbIII 
conjugates with either glutathione, T(SH)2 or both. SbIII/thiols conjugates can be 
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sequestered by ABC-thiol transporter MRPA (MRPA) into intracellular organelles or 
pumped out by an uncharacterized transporter (Figure 8). Previous studies also shown 
that an increase in MRPA alone cannot confer resistance to SbIII in Leishmania and other 
factors are needed. GSH1 seems to play a major role in the resistance conferred by 
MRPA, and although an increase of GSH1 substantially increases the resistance when 
conjugated with an increase of MRPA, it was shown that normal levels of GSH1 are 
enough for the MRPA-related resistance to occur [Callahan et al., 1994; Grondin et al., 
1997; Haimeur et al., 2000; Croft et al., 2006; Ashutosh et al., 2007; Jeddi et al., 2011]. 
 
 
3.2. Miltefosine 
 
Miltefosine (MILT) also known as hexadecylphosphocholine was only recently 
introduced as an antileishmanial drug but even before this introduction concerns about 
the emergence of resistance to MILT were already present. Data from a phase IV 
Figure 8. Overview of Leishmania pathways involved in response and resistance to pentavalent antimonials 
(SbV). ACR2 – Arsenate reductase 2; AQP1 – aquaglyceroporin; GSH – Glutathione; GSH1 – Gamma-
glutamylcysteine synthase; MRPA – ABC-thiol transporter MRPA; ROI – Reactive oxygen intermediates; RNI – 
Reactive nitrogen intermediates; SbIII – Trivalent antimonials; SbIII/thiols – Conjugates of SbIII with T(SH)2 and/or GSH; 
TDR1 – Thiol-dependent reductase 1; TR – Trypanothione reductase; T(SH)2 – Trypanothione; T(S)2 – Trypanothione 
disulfide. 
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treatment trial show a relapse rate twice as high when compared to first-line treatment. 
The multitude of proposed mechanisms of action for MILT and the contradictory data 
from several studies may indicate that more than one molecular site of action is used. 
These mechanisms seem to be related to alterations in the lipid metabolism, mediation 
of apoptosis-like cell death, mitochondrial dysfunction and immunomodulation. A 
perturbation of ether-phospholipid metabolism related to inhibition of glycosomal alkyl-
specific acyl-CoA acyltransferase was found in Leishmania when treated with MILT. 
Also, a decrease in phosphatidylcholine and an increase in phosphotidylethanolamine 
was observed. This suggests that MILT is responsible for the alteration of the 
composition of the parasite membrane. Apoptosis-like cell death was also reported in 
parasites exposed to MILT. This usually happens after exposure to reactive oxygen 
species (ROS) and lead to DNA fragmentation, nuclear condensation, loss of cell volume 
and consequently cell death. Therefore, MILT may be responsible for disrupting the 
intracellular redox balance of the parasite that allows it to tolerate the ROS inside the 
phagolysosome. The involvement of mitochondrial dysfunction was also investigated 
and the inhibition of cytochrome-c oxidase was observed. This inhibition was responsible 
for a substantial reduction in the mitochondrial membrane potential. As an additional 
contributory factor MILT was shown to have immunomodulatory proprieties, being able 
to enhance interferon-gamma receptors in infected macrophages and thereby increase 
T helper cell type 1 response, necessary to fight the parasite infection [Croft et al., 2006; 
Soto et al., 2007; Dorlo et al., 2012]. 
Emergence of drug resistance to MILT in vivo has not yet been described, although a 
strain of L. infantum with decreased susceptibility was recently isolated from a non-
responsive HIV/VL patient. In vitro studies demonstrated that it is easy to induce 
resistance to MILT in Leishmania. These studies concluded that a defect in drug 
internalization and increased drug efflux from the parasite were the possible mechanisms 
of resistance. Two Leishmania lipid translocases, putative miltefosine transporter protein 
(MT) and MT non-catalytic subunit protein ROS3 play an important role in maintaining 
the phospholipid asymmetry of the parasite membrane. Their low expression was proven 
to be directly related to resistance to MILT, since a lower amount of these proteins leads 
to a decrease in the internalization of the drug into the parasite. Overexpression of P-
glycoprotein MDR1 (MDR1) and ABC subfamily G-like transporters ABCG6 and ABCG4 
was also implicated in MILT resistance, being responsible for a decrease in drug 
accumulation in the parasite. Several single point mutations in the genes coding these 
proteins were also observed in vitro [Coelho et al., 2012; Dorlo et al., 2012; Luque-Ortega 
et al., 2012]. 
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3.3. Amphotericin B 
 
Amphotericin B (AmB) is a polyene antibiotic that binds preferentially to ergosterol, 
the major sterol of Leishmania. AmB binding to ergosterol causes the formation of 
transmembrane AmB channels which alter the permeability to cations, water and glucose 
and affect membrane-bound enzymes. These alterations eventually lead to the parasite 
death. Studies have also shown that AmB binds to the cholesterol present in the 
macrophages, decreasing the ability of the parasite to enter these cells and modulates 
macrophage activity by inducing the production of proinflammatory cytokines and ROS 
[Chia & McManus, 1990; Mozaffarian et al., 1997]. 
Apart from relapses of VL patients co-infected with HIV, no other signs of resistance 
were found so far for AmB. These relapses were also proven not to be a cause of 
resistance of the parasite to AmB, thus all the data available arrive from in vitro 
experiments. AmB-resistant Leishmania showed significant changes in membrane sterol 
composition, where most of the ergosterol was replaced by a precursor, cholesta-5,7,24-
trien-3β-ol. This was a result of a loss of function of sterol-methyltransferases responsible 
for ergosterol biosynthesis whose genes most likely suffered deletion amplification [Croft 
et al., 2006; Paila et al., 2010]. 
 
 
3.4. Strategies to combat drug resistance 
 
There are several strategies to combat drug resistance that only now are starting to 
be taken into consideration, mostly because of the increase and spreading of resistance 
to SbV.  
The variation of parasite sensitivity to several drugs is a problem in areas endemic for 
more than one species of Leishmania. This can be solved by improvement of the 
diagnostic methods, especially non-invasive tests with high sensitivity and specificity for 
precocious detection of antileishmanial antigen and able to distinguish different species 
of Leishmania. A precocious, robust and accurate diagnosis would improve the 
treatment, allowing a correct choice of drug, the right dosage and determine the period 
of treatment. This would also aid to minimize the possible failure of treatment and 
consequently reduce the probability of the emergence of drug resistance. 
The monitoring of the therapy also plays an important role. One of the causes for the 
appearance of drug-resistant Leishmania is believed to be the reduced level of 
compliance with treatment, since disease symptoms disappear before the full clinical 
cure. A better strategy in this field is needed, perhaps the implementation of control 
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programs like the ones already in practice by the World Health Organization for 
tuberculosis. These programs rely on the directly observed treatment, short-course 
(DOTS) strategy. The DOTS strategy combines government commitment, case 
detection, standardized treatment, direct observation of the patience and compliance 
with treatment by healthcare workers, regular drug supply and standardized recordings 
and, a reporting system that allows assessment of the treatment results. 
The distribution and cost of the drugs are also another important factor. The elevated 
cost of the more efficient and safe drugs and their unavailability in several public health 
institutions (especially in countries of low income) is something that needs to be 
changed. Either by researching on new, highly effective and cheaper drugs or by 
implementation of programs by governments or private institutions able to distribute the 
right drugs among those that need them. 
Another way to prevent the emergence of drug resistance is to monitor the 
susceptibility of the parasite strains to the common drugs. This could be done by create 
and implement a routine test in endemic areas with high risk of resistance emergence. 
This would allow a better choice of treatment and higher efficacy rate in the elimination 
of the disease. Also, the use of combination therapies would be facilitated. Given that 
the possibility of resistance development to a single therapeutic agent is high, the chance 
of developing simultaneous resistance to two compounds with different targets would 
lower the probability of resistance emergence by a great amount. 
Furthermore, the most relevant strategy is probably the research of new drugs and 
new targets. An adequate amount of drugs with different targets and no cross-resistance 
is the most efficient way to avoid the appearance of drug resistance [Sundar, 2001; 
Sundar & Rai, 2002; Croft et al., 2006; Jain, 2010; Antinori et al., 2012]. 
 
 
3.5. New drugs 
 
In spite of all the currently used antileishmanial drugs, none of them conjugates high 
efficiency, low toxicity and an affordable cost. So it is still a priority the development of 
new therapeutic compounds for leishmaniasis. 
Current research on new antileishmanial drugs is especially focused on already 
existing compounds used for the treatment of other diseases, compounds from natural 
sources, like plants, and even formulations already in use as herbicides. Several 
compounds of diverse molecular structure with potential antileishmanial activity have 
been isolated. Among these compounds, the most notable are dinitroanilines, alkaloids, 
particularly indoles, naphtylisoquinolines, bisbenzylisoquinolines, benzoquinolizidines, 
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triterpenes, steroids, saponins, sesquiterpenes, diterpenes and flavonoids, mainly 
isoflavones and chalcones [Marques et al., 2008; Passero et al., 2013]. 
 
 
4. Dinitroanilines derivatives 
 
The potential of trifluralin (TFL, Figure 9a) for the treatment of leishmaniasis was 
recently demonstrated. TFL is a dinitroaniline, widely used in herbicidal formulations, that 
binds to the parasite tubulins (the main structural component of microtubules) inhibiting 
the growth and differentiation of the parasite. And, since it lacks affinity to animal tubulins, 
is not toxic to mammals. However, its use is limited by its low water solubility and easy 
sublimation. To overcome this, chemical modifications were introduced and several TFL 
analogues (TFL-A) were screened for better solubility and improved antileishmanial 
activity [Esteves et al., 2010]. The analogues TFL-A3 (Figure 9b) and TFL-A6 (Figure 
9c) presented high antileishmanial activity 
and low cytotoxicity. Oryzalin (ORZ, 
Figure 9d), another dinitroaniline also 
showed good in vitro antileishmanial 
activity and low cytotoxicity [Lopes et al., 
2012].  
Mice previously infected with L. 
infantum and treated with TFL-A3, TFL-
A6, ORZ or the conventional 
antileishmanial drug STB demonstrated 
that a complete elimination of Leishmania 
was not attained [Marques et al., 2008], 
therefore it was theorized that the 
surviving parasites were less susceptible 
or resistant to the drug used in the 
treatment. 
  
Figure 9. Chemical structure of TFL (a), TFL-A3 (b), 
TFL-A6 (c) and ORZ (d). 
26 
II. OBJECTIVES 
II. OBJECTIVES 
 
Since it was theorized that parasites that survived exposure to conventional and new 
antileishmanial drugs in animal models were less susceptible or resistant to the drug 
used in the treatment, the main objective of this study was to analyze the level of gene 
amplification of resistance-related genes in these L. infantum strains and evaluate the 
resistance achieved by the parasite to the different drugs used. 
To evaluate the antileishmanial activity of a commonly used antileishmanial drug 
(STB) and new chemically synthesized compounds (ORZ, TFL-A3 and TFL-A6) and their 
potential to generate drug-resistant parasite strains, previously infected mice were 
treated with these compounds, and the parasites that survived to the treatment quantified 
and collected for DNA extraction and real-time PCR analysis.  
Previous studies linked the amplification of four specific genes to drug resistance in 
clinical strains of L. infantum: the genes for energy depended transporters MRPA 
(MRPA, RefSeq XM_001465669.1) and MDR1 (MDR1, RefSeq XM_001468445.1), the 
gene for the enzyme GSH1 (GSH1, RefSeq XM_001464941.1) involved in glutathione 
and trypanothione synthesis and, the gene for pteridine reductase 1 (PTR1, RefSeq 
XM_001465671.1) an enzyme involved in the folate metabolic pathways [Mary et al., 
2010]. Therefore, these four genes (MRPA, MDR1, GSH1 and PTR1) were selected as 
targets for gene amplification analysis. 
To analyze the gene amplification in an in vitro scenario, L. infantum promastigotes 
were made resistant to several antileishmanial compounds (MGA, MILT, TFL-A3 and 
TLF-A6) and the level of gene amplification accessed by real-time PCR. For absolute 
quantification by real-time PCR to be possible, the number of copies of each gene were 
normalized relatively to the number of copies of the single copy invariant gene for DNA 
polymerase alpha catalytic subunit (POL1, RefSeq XM_001464606.1) for every sample 
analyzed. 
By investigating the differences in gene copy number of the selected genes in the 
different resistant strains it is also possible to clarify the mechanisms responsible for the 
parasite survival when exposed to antileishmanial compounds.  
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1. In vivo infection and treatment 
 
1.1. Animals and parasites 
1.1.1. Animals 
 
A total of 65 female BALB/c Mus musculus mice were used in three independent 
experiments. All the animals were infected with L. infantum. For the first two experiments 
20 mice were randomly divided into four groups of five mice each. One untreated control 
group and each of the other three groups treated with a different drug: STB, TFL-A3 and 
TFL-A6. In the third experiment 25 mice were randomly divided into five groups of 5 mice 
each. One untreated control group and each of the remaining four groups were treated 
with a different drug: STB, TFL-A3, TFL-A6 and ORZ. The animals were purchased and 
maintained in the IHMT animal facility according to the EU requirements (86/609/CEE) 
and Portuguese law (DR DL129/92 and Portaria 1005/92). 
 
 
1.1.2. Parasites 
 
L. infantum zymodeme MON-1 (MHOM/PT/89/IMT151) was used to infect BALB/c 
mice in these experiments. L. infantum MON-1 was maintained in the laboratory by 
successive passages in BALB/c mice. The spleens of infected mice were extracted and 
homogenized with a tissue disaggregator with 50 µm separator screen (Medicons, 
Syntec International, Ireland) to isolate a suspension of single cell amastigotes. This cell 
suspension was added to Schneider medium (SCHN, Sigma-Aldrich, Germany) 
supplemented with 10% (v/v) of heat-inactivated (30 minutes at 56ºC) fetal bovine serum 
(FBS, Sigma-Aldrich), penicillin-streptomycin (Biochrom, Germany) at 100 U/ml and 100 
µg/ml respectively (complete SCHN medium), and incubated at 24ºC. In axenic cultures 
the intracellular amastigotes change into free metacyclic promastigotes. 
 
 
1.2. Infection 
 
Concentration (promastigotes/ml) from cultures of metacyclic promastigotes was 
calculated by optical microscopy using a Neubauer Chamber. The culture was 
centrifuged at 1800xg for 10 minutes and resuspended in the appropriate amount of 
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sterile saline solution (0.90% m/v of NaCl) in order to achieve a concentration of 1x107 
promastigotes/ml. Each mouse was intraperitoneally (IP) inoculated with 100 µl of this 
solution. 
 
 
1.3. Treatment 
 
Forty-five days post infection mice were randomly sorted into groups of 5 mice each. 
The control group was IP injected with 200 µl of trehalose-citrate buffer (10 mM sodium 
citrate, 135 mM NaCl, 29 mM trehalose, pH 5.5) once a day for 10 days. Groups treated 
with TFL-A3 and TFL-A6 (dissolved in trehalose-citrate buffer with 5% Tween 80) were 
IP injected with a dose of 25 mg TFL-A/kg/day for 10 consecutive days. The group 
treated with ORZ (dissolved in trehalose-citrate buffer with 5% Tween 80) was 
intravenously injected for 10 consecutive days with a dose of 25 mg ORZ/kg/day. Fifty 
days post infection, the mice treated with STB were injected subcutaneously with 15 mg 
STB/kg/day for 5 consecutive days. 
 
 
1.4. Parasitic load determination 
 
Three days after the conclusion of the treatment mice were sacrificed and their spleen 
aseptically removed and weighted. The spleens were homogenized individually in 4 ml 
of complete SCHN medium using Medicons. Viable parasite loads were estimated by 
limiting dilution assay (LDA) in 96 well plates. An additional 1:2 dilution of the cell 
suspension was made and 200 µl of this cell suspension was placed in the first well of 
each row of 96 well plates and fourfold serial dilutions were made until the last column 
of the plate. For each homogenized cell suspension, four rows of a 96 well plate were 
used in order to have four replicates. The LDA plates were sealed and incubated during 
15 days at 24ºC. After incubation each well was examined by optical microscopy and 
labelled as positive if promastigotes were present or negative if no parasites were 
detected. The highest dilution for which the well contained promastigotes was used to 
calculate the number of parasites per gram of tissue (ppg) as follows: 
 
ppg = �Reciprocal titer of highest positive dilution × Volume of cell suspensionVolume of first well × Dilution factor �
Weight of homogenized tissue (g)  
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The content of the highest positive dilution wells for each group was collected, washed 
three times by centrifugation at 1800xg for 10 minutes with PBS (Lonza, Belgium) and 
frozen at -80ºC in PBS for posterior DNA extraction. 
 
 
2. In vitro resistant parasites 
 
2.1. Parasites 
 
L. infantum zymodeme MON-1 (MHOM/PT/89/IMT151) was the strain used to 
generate drug-resistant promastigotes in vitro. L. infantum MON-1 was maintained in the 
laboratory as described in 1.1.2. and never had contact with any type of antileishmanial 
drug. 
 
 
2.2. Drug-resistant promastigotes 
2.2.1. Drug dilutions and plating 
 
Four antileishmanial drugs were used to generate in vitro drug-resistant 
promastigotes: MGA, MILT, TFL-A3 and TFL-A6. A solution of commercial Glucantime® 
(Merial, France) with 81 mg/ml of meglumine antimoniate and a solution of commercial 
Milteforan® (Virbac, France) with 20 mg/ml of miltefosine were used. These initial 
solutions were diluted to a concentration of 64 mM and 1 mM in SCHN medium, 
respectively. The purified TFL-A3 and TFL-A6 compounds were dissolved in a solution 
of DMSO/Ethanol (1:1) to a concentration of 65 mM. These initial solutions were then 
diluted in SCHN medium to a final concentration of 2 mM. For each of the compounds 
seven twofold serial dilutions were made in SCHN medium. A different dilution was used 
for each row of a 96 well plate. Each well was filled with 100 µl of the appropriate dilution. 
A control plate where all the wells were filled with 100 µl of SCHN medium was also 
performed. 
Concentration (promastigotes/ml) of L. infantum culture was calculated by optical 
microscopy using a Neubauer Chamber as described in 1.2.. The culture was centrifuged 
at 1800xg for 10 minutes and resuspended in SCHN medium supplemented with 20% 
FBS in order to achieve a concentration of 1x108 promastigotes/ml. Every well of the 96 
well plates with the drug dilutions were filled with 100 µl of L. infantum culture. The plates 
were sealed and incubated at 24ºC for 96 hours. 
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2.2.2. Evaluation of resistant promastigotes 
 
After incubation, each well was examined by optical microscopy and labelled as 
positive if live promastigotes were present or negative if no live promastigotes were 
detected. The highest dilution for which the well contained live promastigotes was 
centrifuged at 130xg for 10 minutes to exclude all the dead promastigotes, the 
supernatant was collected and washed three times by centrifugation at 1800xg for 10 
minutes in sterile saline solution and resuspended in 1 ml of complete SCHN medium. 
The concentration (promastigotes/ml) was calculated for each sample and the cultures 
were grown in complete SCHN medium with the drug concentration of the original well 
until enough promastigotes were present to repeat the steps in 2.2.1.. This continuous 
process took place until the highest dilution for which the well contained live 
promastigotes had double the drug concentration of the lowest dilution with no live 
promastigotes for the first time this process was done. 
 
 
2.2.3. Sample collection 
 
After the increase of drug resistance by fourfold, the content of the wells was collected 
and centrifuged at 130xg for 10 minutes to exclude all the dead promastigotes, the 
supernatant was collected and washed three times by centrifugation at 1800xg for 10 
minutes in PBS and frozen at -80ºC in PBS for posterior DNA extraction. 
 
 
3. Primer selection and plasmid cloning 
 
3.1. Primer selection and optimization 
 
Using Primer-BLAST software [Ye et al., 2012] appropriate primers were selected for 
the genes studied (Table 1). Primers (Stabvida, Portugal) were optimized by PCR 
changing the annealing temperature (TAN) and duration of cycles until the desired 
fragment was the only DNA amplified from a sample of L. infantum DNA, and no 
amplification whatsoever was observed for samples of mice (Figure 10). Initial TAN of 
each gene fragment was calculated subtracting 5ºC to the primer melting temperature 
specified by the manufacturer of the primers. TAN was gradually increased by 0.5ºC until 
the required amplification specifications were met. Amplification was done in 20 µl of a 
mixture containing 2 µl of sample, 2 µl of 10x NH4 Reaction Buffer (Bioline, UK), 0.8 µl 
of 50 mM MgCl2 solution (Bioline), 0.5 µl of 100 mM dNTPs solution (Bioline), 0.4 µl of 
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20 pmol/µl forward primer solution and reverse primer solution, 0.2 µl of 5 U/µl BIOTAQ 
DNA Polymerase solution (Bioline) and 13.7 µl of ultra-pure water. Optimized conditions 
obtained for amplification were 5 minutes at 95ºC for complete DNA denaturation, 30 
cycles of 30 seconds at 95ºC, 15 seconds at primer/gene specific TAN (Table 1) and 10 
seconds at 72ºC, and a final step of 3 minutes at 72ºC to guarantee complete elongation 
of most PCR products initiated during the last cycle. Samples were analyzed by DNA 
electrophoresis using a gel with 3% (m/v) agarose in Tris-acetate-EDTA (TAE) buffer 
(Merck, USA) containing 0.1 µl/ml of 10000x GelRed Nucleic Acid Stain (Biotium, USA). 
 
 
Gene Primers Fragment Size TAN (ºC) 
POL1 FW - 5' CTGCAGCGCCAAAGGTCTACCC 3' RV - 5' TCTTGCCGAGTTGCTGTGCGAG 3' 86 bp 62.0 
GSH1 FW - 5' CCCGGCATTTCTGGCTCTCAGC 3' RV - 5' GCGATAGTCAGCCAGCGCACAT 3' 84 bp 63.5 
MDR1 FW - 5' GGAGGGTGACACAAGCGACACG 3' RV - 5' CGACGCGATCCGCCTTCATGTT 3' 89 bp 62.0 
MRPA FW - 5' CCGCTCGCGGACCACATTGT 3' RV - 5' TCGCCGCAAAGGCAGCGTAA 3' 76 bp 62.0 
PTR1 FW - 5' ACGTGCTCGTGAACAACGCCTC 3' RV - 5' ATCTCCGACACAGGGCACGTGG 3' 86 bp 65.5 
Table 1. List of forward (FW) and reverse (RV) primers, base pair number (bp) of amplified fragment and 
primer annealing temperature (TAN) for each gene studied. 
 
 
Figure 10. Electrophoresis gel showing the amplified fragments of the genes POL1, MRPA, MDR1, GSH1 and 
PTR1. Wells were loaded with mouse DNA (Mouse), Leishmania DNA (Leish) and a control without DNA (Neg). POL1 
(POL1), MRPA (MRPA), MDR1 (MDR1), GSH1 (GSH1) and PTR1 (PTR1) fragments were amplified at 86 bp, 76 bp, 
89 bp, 84 bp and 86 bp, respectively. 
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3.2. Plasmid cloning 
 
Gene fragments were again amplified by PCR and 2 µl of the PCR product was 
analyzed by DNA electrophoresis to confirm amplification was done correctly. The 
remaining PCR product (18 µl) was purified using innuPREP DOUBLEpure Kit (Analytik 
Jena AG, Germany) following the manufacturer’s instructions and 2 µl of the purified 
product was again analyzed by DNA electrophoresis. The remaining purified fragment 
product was introduced into a circular plasmid using pGEM®-T Easy Vector Systems 
(Promega, USA) as described in the manufacturer protocol. Competent Escherichia coli 
strain JM109 was used for plasmid cloning. E. coli JM109 was grown overnight in solid 
M9 medium (0.6% Na2HPO4, 0.3% KH2PO4, 0.05% NaCl, 0.1% NH4Cl, 0.2% MgSO4, 
0.01% CaCl2, 0.4% Glucose and 1.5 % Agar in distilled water, all percentages in m/v) 
supplemented with 1 mM of thiamine. After incubation a colony was selected and grown 
in 5 ml of LB broth EZMIX (Sigma-Aldrich) overnight at 37ºC. Five ml of overnight culture 
were inoculated into 500 ml of LB medium and left to grow at 37ºC in a rotary shaker at 
250 rpm until OD600 reached 0.4. The bacterial culture was then pelleted by centrifugation 
at 1000xg for 10 minutes at 4ºC and resuspended in 50 ml of ice-cold transformation and 
storage solution [TSS - LB with 10% (m/v) of PEG 8000, 5% (v/v) of DMSO and 50 mM 
of MgCl2] [Chung et al., 1989]. Aliquots of this solution were prepared, frozen with liquid 
nitrogen and then placed on -80ºC for posterior use. Frozen aliquots were then thawed 
on wet crushed ice and 50 µl of thawed competent cells transferred to 2 ml tubes 
previously chilled on ice. Two µl of plasmid with the gene fragment insert were added to 
these tubes and incubated on ice for 30 minutes. Tubes were then subjected to heat 
shock in a water bath at 42ºC for 60 seconds and placed on ice again for 2 minutes. To 
each tube 500 µl of Super Optimal broth with Catabolite repression (SOC, Invitrogen, 
USA) was added and incubated at 37ºC with shaking at 250 rpm for 3 hours, to allow the 
cells to express antibiotic resistance. 250 µl of the cell solution was then plated on LB 
agar (LB with 1.5% (m/v) of agar) supplemented with 100 µg/ml of ampicillin (Sigma-
Aldrich), 80 µg/ml of X-Gal (Sigma-Aldrich) and 0.5 mM of IPTG (Sigma-Aldrich) and 
incubated at 37ºC for 18 hours. The use of this specific E. coli strain and the pGEM®-T 
Easy vector allowed to differentiate the colonies containing the plasmid only from the 
colonies with the plasmid and the insert fragment by blue/white color screening and 
resistance to ampicillin. The white colonies were picked and incubated in LB 
supplemented with 100 µg/ml of ampicillin overnight at 37ºC with shacking at 250 rpm. 
The isolation of plasmid DNA was then made using the innuPREP Plasmid Mini Kit 
(Analytik Jena AG) according to the manufacturer protocol. The plasmid DNA was 
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analyzed by PCR and DNA electrophoresis with the specific primers for the insert 
fragment in order to confirm its presence in the plasmid. 
 
 
4. Quantification of gene number by real-time PCR 
 
4.1. DNA extraction 
 
DNA of the samples collected from in vivo and in vitro experiments was extracted 
using the innuPREP DNA Mini Kit (Analytik Jena AG) according to the manufacturer 
protocol and stored at -20ºC for posterior use. 
 
 
4.2. Real-time PCR 
 
In order for absolute quantification to be possible calibration curves for each gene 
were made using the plasmids with the insert fragment described in 3.2.. The plasmid 
DNA was quantified and, for each gene 1:5 serial dilutions were made starting from 250 
pg/µl to 0.016 pg/µl in ultra-pure water. A posterior 1:2 dilution of each of the previous 
dilutions was made in order to load the real-time PCR reaction mixture with 2 µl of each 
dilution instead of 1 µl. Samples collected as described in 1.4. and 2.2.3. were analyzed 
in triplicate for each gene by this technique. For each sample, 20 µl of the real-time PCR 
reaction mixture was prepared with 2 µl of sample, 10 µl of SensiFAST SYBR Lo-ROX 
(Bioline), 0.15 µl of 20 pmol/µl forward primer solution, 0.15 µl of 20 pmol/µl reverse 
primer solution and 7.7 µl of ultra-pure water. Amplification was done in an Applied 
Biosystems 7500 Fast Real-Time PCR System thermal cycler (Applied Biosystems, 
USA) and the conditions were 5 minutes at 95ºC for complete DNA denaturation, 40 
cycles of 30 seconds at 95ºC and 30 seconds at primer/gene specific TAN (Table 1) for 
annealing and extension, and 90 cycles of 10 seconds at starting temperature of 50ºC 
with an increment of 0.5ºC for each cycle. The fluorescence levels of each sample were 
analyzed in real time by the thermal cycler and the amount of fragment DNA calculated 
in comparison to the calibration curves for each gene. The number of copies was 
calculated as follows, were 9.1x1011 is the amount of DNA base pairs in 1 µg of DNA and 
3015 is the length in bp of the plasmid used: 
 Gene copy number = 9.1×1011 × quantity (µg) 
3015 + insert length (bp) 
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The results for each gene of each sample were divided by the copy number of POL1 
for the same sample, in order to normalize the results. 
 
 
5. Statistical analysis 
 
As stated before, three independent in vivo experiments were conducted for the drugs 
STB, TFL-A3 and TFL-A6. The statistical analysis was done using the non-parametric 
Mann-Whitney U test for two independent samples. The values obtained for parasitic 
load and gene copy number were compared between the study group (mice treated with 
STB, TFL-A3, TFL-A6 or ORZ) and the control group (not treated mice). 
Three independent in vitro experiments were conducted for the drugs MGA, MILT, 
TFL-A3 and TFL-A6. The statistical analysis was done using the non-parametric Mann-
Whitney U test for two independent samples. The values obtained for gene copy number 
were compared between the study group (promastigotes resistant to MGA, MILT, TFL-
A3 or TFL-A6) and the control group (wild-type promastigotes). 
All the data analysis was performed using the software IBM SPSS Statistics version 
22.0 (IBM, USA). A significance level of 5% (p≤0.05) was used to evaluate statistical 
significance of the data analyzed. 
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1. In vivo experiments 
 
1.1. Parasitic load 
 
The control group, infected and not treated (Untreated) mice, for the experiments with 
the TFL analogues showed a mean value of 1.18x104 viable promastigotes per gram of 
spleen. The group treated with STB presented a significant (p=0.022) decrease of 
parasitic load (2.56x102 viable promastigotes per gram of spleen) pointing to 97.84% of 
parasite inhibition when compared to the Untreated group. Mice treated with TFL-A3 
presented a reduction of 36.90% in parasite load, however, this reduction to 7.48x103 
viable promastigotes per gram of spleen 
was not statistically significant. Mice 
treated with TFL-A6 showed 4.57x103 of 
viable promastigotes per gram of spleen 
pointing to a significant (p<0.001) 
reduction of 96.14% in parasite burden 
(Figure 11). 
In the experiment with ORZ the 
Untreated group presented 1.48x104 
viable promastigotes per gram of spleen. 
The treatment with STB and ORZ reduced 
parasitic load to 2.56x102 (p=0.020) and 
2.15x102 (p=0.014) viable promastigotes 
per gram of spleen respectively, showing 
a 98.27% and 98.55% of inhibition in 
parasite replication (Figure 12).  
 
 
1.2. Gene amplification 
 
The parasites from untreated mice (WT), showed a mean of 1.29 copies of the gene 
GSH1 (Figure 13a), 9.82 copies of MDR1 (Figure 13b), 0.90 copies of MRPA (Figure 
13c), and 0.76 copies of PTR1 per parasite (Figure 13d). Parasites isolated from mice 
treated with STB presented a significant increase in the number of copies of MDR1 
(p=0.015, 21.14 copies per parasite) and PTR1 (p=0.006, 1.09 copies per parasite), 
Figure 11. Parasitic load values on the mice treated with 
STB, TFL-A3 and TFL-A6. Viable parasites of untreated 
mice (Untreated) and of mice treated with STB (STB), TFL-
A3 (TFL-A3) or TFL-A6 (TFL-A6) were estimated by limiting 
dilution assay. * (p<0.05) indicates statistically significant 
values when compared to Untreated group. 
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when compared with WT. No significant 
differences were found for MRPA and GSH1 
genes. Parasites isolated from mice treated 
with TFL-A3 displayed a significant increase 
in the copy number of MDR1 (p<0.001, 24.74 
copies per parasite) when compared with 
WT. No significant differences were noted for 
the genes GSH1, MRPA and PTR1. For the 
parasites of the group treated with TFL-A6 
there was a significant increase in number for 
the genes MDR1 (p<0.001, 17.28 copies per 
parasite), MRPA (p=0.005, 2.33 copies per 
parasite) and PTR1 (p<0.001, 1.31 copies 
per parasite), when compared to gene copy 
number of WT. No significant changes were 
seen for GSH1. For parasites that survived 
the treatment with ORZ the results show an increase in copy number for the genes GSH1 
(p=0.002, 1.97 copies per parasite), MDR1 (p<0.001, 15.87 copies per parasite) and 
PTR1 (p=0.006, 1.59 copies per parasite). No alteration was noted for the number of 
copies of MRPA (Figure 13). 
 
 
2. In vitro experiments 
 
2.1. Effective drug concentration 
 
After the first 96 hours of incubation the effective concentration of the drugs able to 
kill all the parasites (EC100) was 8.00 mM for MGA, 15.63 µM for MILT, 125.00 µM for 
TFL-A3 and, 15.63 µM for TFL-A6. After several cycles of exposure to the drugs the 
EC100 for each drug reached 32.00 mM for MGA, 62.50 µM for MILT, 500 µM for TLF-A3 
and 62.50 µM for TFL-A6. 
 
 
2.2. Gene amplification 
 
The wild-type parasites (WT) showed a mean of 9.97 copies of the gene GSH1 
(Figure 14a), 4.06 copies of MDR1 (Figure 14b), 13.80 copies of MRPA (Figure 14c) and 
Figure 12. Parasitic load values of the mice treated 
with STB and ORZ. Viable parasites of untreated mice 
(Untreated) and of mice treated with STB (STB) or ORZ 
(ORZ) were estimated by limiting dilution assay. * 
(p<0.05) indicates statistically significant values when 
compared to Untreated group. 
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0.51 copies of PTR1 per parasite (Figure 14d). The parasites made resistant to MGA 
displayed a significant decrease in gene copy number of the gene MDR1 (p=0.001, 3.31 
copies per parasite) and an increase in copy number of the gene GSH1 (p=0.006, 11.99 
copies per parasite) when compared with WT. No significant differences in copy number 
were found for the genes MRPA and PTR1. MILT-resistant parasites showed no 
significant alteration in copy number of the studied genes when compared to WT. On the 
other hand TFL-A3-resistant parasites presented a significant increase of GSH1 copy 
number (p=0.003, 12.25 copies per parasite). No significant differences were noted for 
Figure 13. Mean of copy number of the genes GSH1, MDR1, MRPA and PTR1 per parasite. Gene copy numbers 
of parasites isolated from mice treated with ORZ (ORZ), STB (STB), TFL-A3 (TFL-A3) and TFL-A6 (TFL-A6) and from 
non-treated mice (WT) were determined by quantitative real-time PCR. * (p<0.05) indicates statistically significant 
values when compared to WT. 
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the copy number of MDR1, MRPA or PTR1. TFL-A6-resistant parasites revealed a 
significant increase of GSH1 (p=0.001, 17.72 copies per parasite), MDR1 (p=0.003, 5.46 
copies per parasite) and PTR1 (p=0.001, 10.07 copies per parasite) when compared 
with WT. A significant decrease in MRPA copy number (p=0.004, 9.82 copies per 
parasite) was also observed (Figure 14). 
  
Figure 14. Mean of gene copy number of the genes GSH1, MDR1, MRPA and PTR1 per parasite. Gene copy 
number of MGA (MGA), MILT (MILT), TFL-A3 (TFL-A3) and TFL-A6 (TFL-A6) resistant parasites (in vitro) and of wild-
type parasites (WT) were determined by quantitative real-time PCR. * (p<0.05) indicates statistically significant values 
when compared to WT. 
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1. Antileishmanial activity of the drugs 
 
From the drugs studied the one with the best antileishmanial activity and future 
potential is TFL-A6, although the results for ORZ seem also very promising. 
TFL-A3 showed a weak antileishmanial activity in vivo and therefore its use in this 
formulation was ruled out. However, this low activity may be related to the delivery of the 
drug to the infected areas in the host and its internalization by the infected macrophages, 
since previous in vitro studies showed great antileishmanial activity against Leishmania 
[Esteves et al., 2010]. 
The antileishmanial activity of TFL-A6 was comparable to STB (96.14% and 97.84% 
parasite reduction, respectively), a commonly used antileishmanial drug. TLF-A6 can be 
a promising drug to be used for the treatment of visceral leishmaniasis. However, as it 
happens for STB in animal models, this formulation was not able to kill all the parasites 
in the host which is a major concern because it may lead to the selection of resistant 
parasites. Similarly the treatment with ORZ was not able to clear all the parasites and 
again, the emergence of drug resistant strains from the surviving parasites should be 
strongly considered.  
 
 
2. Gene amplification and mechanisms of drug action 
 
By analyzing the DNA of Leishmania parasites that survived to treatment with STB, 
TFL-A3, TFL-A6 or ORZ it was possible to determine the number of gene copies of four 
genes associated with drug resistance, MDR1, MRPA, GSH1 and PTR1, in the parasites. 
By surviving the treatment it was hypothesized that this parasite would have some sort 
of advantage in surviving the contact with the drugs used, being less susceptible or 
resistant to the drugs. 
The parasites that survived the treatment with STB presented a significant increase 
in copy number of the genes MDR1 and PTR1. MDR1 is a gene responsible for the 
expression of the P-glycoprotein MDR1, which is required for the extrusion of drugs. The 
amplification of this gene is associated with resistance to several hydrophobic drugs, 
however, no direct relation to resistance to hydrophilic drugs, like SbIII, was demonstrated 
so far. The amplification of this gene was already reported for L. infantum isolated from 
clinical samples from VL cases resistant to antimonials. However, because of the clinical 
nature of the samples, there were doubts about if MDR1 amplification was because of 
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other drugs used for treatment of other diseases in the patients [Mary et al., 2010; Jeddi 
et al., 2011]. In the present study, the group of mice treated with SbIII was not subjected 
to any other treatment, therefore we can conclude that MDR1 is involved in the efflux of 
SbIII and, by consequence, in resistance to this antileishmanial compound. The 
amplification of PTR1 suggests that less sensitivity to STB can be associated to the folate 
metabolic pathways. Leishmania requires an exogenous source of folate and 
unconjugated pteridines to replicate and infect the vertebrate host. The enzyme PTR1 is 
responsible for the reduction of biopterin into H4-biopterin, which was also shown to play 
a key role in the biosynthesis of nitric oxide and to be connected to the sensitivity of 
Leishmania to oxidants [Nare et al., 2009; Ong et al., 2011; Vickers & Beverley, 2011]. 
These evidences lead to two possible conclusions. The amplification of PTR1 may give 
an advantage in the surviving of the parasites inside the host macrophage by protecting 
against oxidative stress, and this way the amplification is not directly related to the drug 
used. On the other hand, PTR1 amplification may decrease the efficacy of SbIII by 
reducing the reactive oxygen and nitrogen intermediates, making the inhibition of 
trypanothione reductase (TR) by SbIII less relevant (Figure 8). 
TFL-A3-surviving parasites only present MDR1 amplification. As stated before, MDR1 
can be responsible for an increase in efflux of TFL-A3. This can be explained by the fact 
that the main targets of MDR1 are hydrophobic compounds and the low water-solubility 
of this drug suggests that it have a hydrophobic structure. 
Three of the four studied genes (MDR1, MRPA and PTR1) showed significant 
amplification in the parasites that survived to TFL-A6 treatment. The resistance to this 
derivative seem to be associated with its accumulation inside the parasite and with 
oxidative/nitrosative stress. The ABC-thiol transporter MRPA was shown to be 
responsible for sequestering SbIII/thiols conjugates into intracellular organelles in the 
parasite. A lower concentration of SbIII was also found inside parasites with amplified 
MRPA. Although is not clear how this happens, it seems to be related to a decrease of 
drug influx and not active efflux, since mutants with amplified MRPA shown rates of SbIII 
efflux similar to wild-type parasites [Callahan et al., 1994; Grondin et al., 1997; Haimeur 
et al., 2000]. Similarly, a decrease of TFL-A6 influx could also occur. This effect in 
conjugation with the survival advantages conferred by the increase of MDR1 and PTR1 
indicate that the parasite can use different mechanisms to survive when under drug 
pressure. 
Once again, the amplification of GSH1, MDR1 and PTR1 in the ORZ-treated parasites 
suggests an association of parasite resistance is related with the increase of drug efflux 
and high protection from oxidative/nitrosative stress. Furthermore, the amplification of 
GSH1 denotes that the mechanism of action of this drug may also be related to the 
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alteration of redox balance inside the parasite, and by consequence the counteraction 
by the parasite involves the glutathione and trypanothione pathways (Figure 8). 
In the in vitro experiments performed, the parasites that were made resistant to the 
drugs MGA, MILT, TFL-A3 or TFL-A6 shown different results when compared to the ones 
achieved in the in vivo experiments. This may be explained by the different 
developmental stages of the parasite in both experiments. While in the in vivo 
experiments the parasite contacted with the drugs when inside the macrophage in the 
amastigote form, in the in vitro experiments the parasite was in promastigote form. 
Differences have been reported in several cellular processes, like metabolism, 
intracellular transport and response to oxidative stress, between intracellular 
amastigotes and axenic promastigotes. Also the fact that some compounds, like SbV, 
need to be metabolized by the macrophage to get activity and that in some cases 
macrophages are the drug targets also contributes to these differences [Vermeersch et 
al., 2009; De Muylder et al., 2011]. The wild-type parasites alone shown a significant 
difference in gene copy number for the genes GSH1, MDR1 and MRPA between the 
parasites from the in vivo and in vitro experiments (Figure 15). 
For the made in vitro MGA-resistant parasites, significant differences were noted for 
the number of gene copies of the genes GSH1 and MDR1. The increase of gene copy 
number for GSH1 can be 
explained by the involvement 
of GSH1 in the glutathione 
and trypanothione pathways, 
responsible for the redox 
balance of the parasite. This 
seems to be enough for the 
survival of the parasite when 
in contact with high concen-
trations of MGA. MGA, like 
all pentavalent antimonials, 
needs to be reduced to SbIII. 
In vivo the reduction of SBV 
to SbIII occurs mainly in the 
host macrophage. In vitro antileishmanial activity of this drug is low when presented to 
axenic promastigotes in culture. There is no direct explanation for the reduction in the 
number of gene copies for MDR1. This characteristic was most likely selected because 
it saves energy, otherwise wasted pumping out SbV from the parasite, which is not 
harmful unless reduced to the trivalent form. 
Figure 15. Comparison between the gene copy number of wild-type 
parasites for the in vivo and in vitro experiments. * (p<0.05) indicates 
statistically significant values between the parasites of in vivo and in vitro 
experiments. 
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For the parasites made resistant to MILT there was no differences in the gene copy 
numbers. This is most likely due to the fact that resistance to MILT appears mostly due 
to point mutations and not amplification. Also, amplification of genes other than the ones 
studied may be responsible for resistance to MILT. 
The parasites made resistant to TFL-A3 only shown amplification for the gene GSH1. 
This, as stated before, is most likely related to the redox balance inside the parasite 
which seems to suffice for the parasite survival. 
The in vitro TFL-A6-resistant parasites shown significant amplification for the genes 
GSH1, MDR1 and PTR1 associated with a significant decrease in copy number of MRPA 
gene. Amplification of GSH1 and MDR1 are connected to the maintenance of redox 
balance and efflux of the drug from the parasite, respectively. The high level of 
amplification of PTR1 (ten times more than WT) in conjugation with the amplification of 
GSH1 indicate that the mechanism of action of this drug in the promastigote is related to 
redox imbalance and oxidative stress. TFL-A6 resistance can also be connected with the 
availability of biopterins, by inhibiting biopterin transporters or its pathways, for example. 
It was shown before that H4-biopterin is essential for promastigote replication [Ong et al., 
2011]. The reduced number of MRPA gene copies seems to indicate that the 
accumulation of TFL-A6 inside intracellular organelles may be a disadvantage to the 
survival of the promastigote when in culture. 
 
 
3. General conclusions and future perspectives 
 
This study allowed to conclude that even though some drugs may demonstrate a good 
antileishmanial potential in vivo, their potential as good antileishmanial drugs may be 
less than ideal. The fact that a short-term period of treatment (10 days) was enough for 
such significant changes in the parasite DNA leads to the conclusion that in a wide-range 
drug-use scenario many cases of drug-resistant parasites may appear. Considering that 
amplification of the same genes is shared between the classical antileishmanial drugs 
(STB and MGA) and TFL-A6, the clinical use of this new compound may prove ineffective 
at short time. 
These factors should all be taken into consideration when designing and testing new 
antileishmanial drugs. The techniques used in this study should be improved and the 
range of genes studied increased, achieving an effective screening method for the 
potential resistance mechanisms displayed by new drugs. This would not only save time 
when selecting new potential drugs but also prevent unexpected relapses of the disease 
and the emergence of less susceptible parasites due to drug resistance in the future. 
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